New Street Research - Novo Nordisk (novob) Novo Nordisk - Cut to Sell - The Wood for The Trees (TP DKK 460)

Report

New Street Research

Dominic Rose ...

Naresh Chouhan

EUR 4411.00 For Business Accounts Only

Novo Nordisk - Cut to Sell - The Wood for The Trees (TP DKK 460)

Whilst the Wegovy scrips are scrutinised on literally a daily basis, US Ozempic softness seems to have been ignored despite Ozempic being 2x bigger than Wegovy in terms of global sales. New analysis makes us more concerned about Ozempic 2025 sales, than Wegovy. We are now 8% below the mid-point of 2025 guidance on sales & EBIT. We are 40% below consensus by 2030 on Ozempic sales, which could translate to a 16% cut to cons. group EBIT in 2030. We cut our group sales forecasts by 6-10% and EBIT by 7-17% leaving us 12% below cons. sales by 2027. The catalyst path is also unattractive so offers little support for the stock. Our DKK460 PT puts Novo at a 20% PE premium to Sanofi in 2030 & broadly in-line with AZN despite it having less LOE risk. SELL
For access to the full note, please contact Naresh Chouhan ( )

24/03/2025 1 EN

Underlying

Novo Nordisk

See profile

Provider

New Street Research

Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.

New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:

Pan European Telecom Services and Cable
US Telecoms, Cable, Satellite and Towers
Global Emerging Market Telecoms
Japan Telecoms
Asian Internet
Pan European Healthcare
Global healthcare thematic research

We provide debt research on:

Pan European Telecom Services and Cable

See profile

Analysts

Dominic Rose

Naresh Chouhan

Other Reports on these Companies

New Street Research

Novo - Worrying Times (SELL, TP DKK350 [460], 13pgs)

Following the orfo’ P3 data, latest Wegovy scrips & rapidly faltering Ozempic growth, we conduct a wholesale review of our obesity market model, Wegovy & Ozempic scrip models & our Novo financial model. The outcome of this analysis is that we downgrade our 2030 sales by 20% and EPS by 24%. We now assume Novo only achieve a 25% obesity market share by 2030. We are 19% below consensus sales & 23% below EPS in 2030. We also provide a detailed hypothesis as to why US obesity demand growth is so lacklustre & conclude demand growth will be slow in the absence of Medicare approval. PT cut to DKK350 &...

EUR 4411.00

April 22, 2025 April 22, 2025 1 EN

New Street Research

US Tariffs - Broad Tariffs are Highly Unlikely (7pgs)

Following a number of recent events, we discuss in this note what we think is the most likely outcome for the Pharma industry. We show that broad based tariffs on drugs are highly unlikely, that even if it were to happen, the impact of a 20% tariff is

EUR 4411.00

April 17, 2025 April 17, 2025 1 EN

New Street Research

US Tariffs - Transfer Pricing Could Negate Impact (6pgs)

We show that Big Pharma would not have to shift a single element of supply chain to the US and can mitigate most, if not all, of a 20% tariff on drugs, just by changing their transfer pricing strategy. In a scenario where the US corporation tax rate falls to 15% but tariffs are 20%, we show that Big Pharma profits would be unchanged, while the US government tax take would more than double. The losers would be low tax jurisdictions like Ireland, but they would get to keep their manufacturing base, at least in the medium-term. We also show that the impact of 20% tariffs with no tax mitigation wo...

EUR 4411.00

April 3, 2025 April 3, 2025 1 EN

Comcast Post-1Q25 Model Update

What’s new: In this note, we cover changes to our estimates, and comparisons with guidance and consensus. Please see separate notes reviewing results and thoughts following the earnings call. The most significant changes are higher broadband losses and lower EBITDA in 2025. We expect Consensus to increase broadband losses as well as lower EBITDA. No change to thesis. Price target is $38 (+15%).

2h / 29m 2h / 29m 1 EN

Jonathan Chaplin

Jonathan Chaplin

CMCSA: Quick thoughts following the call 1Q25

What’s new: in this note we cover the source of the pressure Comcast is seeing on broadband growth (market vs competition), we cover the potential causes of slower market growth, we cover the causes of competitive pressures and the impact of recent pricing changes, and we touch on implications for ARPU and EBITDA growth.

3h / 49m 3h / 49m 1 EN

Russell Waller

Russell Waller

MasOrange (Equal Weight) Q1 25: Continued synergy delivery; FibreCo on track

MasOrange (MA) has reported a solid set of numbers, subs continue to grow nicely, and EBITDA growth is good again – albeit there is seemingly no SR drop-through, as EBITDA is wholly driven by synergies. Closing of the fibre JV seems to be on track, and we remain of the view that Orange will look to reconsolidate MA in the future (as opposed to an IPO).

EUR 8822.00

6h / 2m 6h / 2m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Novo Nordisk - Cut to Sell - The Wood for The Trees (TP DKK 460)

Novo - Worrying Times (SELL, TP DKK350 [460], 13pgs)

US Tariffs - Broad Tariffs are Highly Unlikely (7pgs)

US Tariffs - Transfer Pricing Could Negate Impact (6pgs)

Comcast Post-1Q25 Model Update

CMCSA: Quick thoughts following the call 1Q25

MasOrange (Equal Weight) Q1 25: Continued synergy delivery; FibreCo on track

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe